ME-3183 is under clinical development by Meiji Seika Pharma and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ME-3183’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
ME-3183 overview
ME-3183 is under development for the treatment of plaque psoriasis (psoriasis vulgaris). It is administered through oral route and acts by targeting phosphodiesterase 4 (PDE4).
See Also:
Meiji Seika Pharma overview
Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider. The company is engaged in providing pharmaceutical, veterinary drugs and chemicals used for agriculture. The company offers Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest, Depromel and others. It operates manufacturing and development technologies, which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers products for human and veterinary care. It operates research centre, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.
For a complete picture of ME-3183’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
